Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals, Inc. reports that CEO Christopher Peetz exercised 40,000 employee stock options at $2.936 per share on August 11, 2025, receiving 40,000 common shares, and then sold 40,000 shares at $62.00 per share. A footnote notes the reported transaction occurred under a Rule 10b5-1 plan adopted on November 22, 2024, and that the stock option is fully vested with an expiration date of March 11, 2029. Following these transactions, Peetz holds 138,641 common shares directly and 208,570 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals has filed a shelf registration providing a framework to offer common stock, preferred stock, debt securities and warrants, and includes a sales agreement to sell up to $200.0 million of common stock. The company commercializes three approved medicines—Livmarli (maralixibat), Cholbam (cholic acid) and Chenodal/Ctexli (chenodiol)—and markets these products in the U.S. and selected international territories through its specialized commercial team. Mirum has expanded its portfolio via an asset acquisition related to chenodiol and Cholbam and obtained worldwide rights to MRM-3379 through a license agreement to develop a Fragile-X treatment. The prospectus describes ongoing clinical programs for Livmarli and volixibat, regulatory designations for volixibat, and confirms Nasdaq listing under the symbol MIRM. The prospectus highlights inherent business risks and reserves broad discretion over use of proceeds, principally for general corporate purposes.
Mirum Pharmaceuticals, Inc. (MIRM) filed a Form 144 reporting the proposed sale of 40,000 common shares acquired by stock option exercise on 08/11/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,480,000 based on the filing and the company has 50,237,647 shares outstanding as shown.
The filing also records a prior sale during the past three months: Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040. The filer certifies they have no undisclosed material adverse information and notes the securities were paid for in cash at acquisition.
Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals (MIRM), reported both non-derivative and derivative transactions affecting her holdings. The filing shows a sale of 10,000 common shares at $58.00, after which her reported direct beneficial ownership stood at 2,426 shares. On the same date she recorded an acquisition-related entry at a $6.27 price for 10,000 common shares, with a reported beneficial ownership figure of 12,426 shares following that transaction.
An employee stock option with a conversion/exercise price of $6.27 covering 10,000 underlying shares is reported and is stated to be fully vested. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan adopted December 16, 2024, and the reporting person is shown as beneficial owner of 40,000 derivative securities following the reported activity.
Mirum Pharmaceuticals CEO Christopher Peetz exercised employee stock options for 40,000 shares of common stock at $2.936 per share on August 7, 2025, then sold 40,000 shares at a weighted average sale price of $55.251022 (range $55.25–$55.485). After these transactions he holds 138,641 shares of common stock directly and 208,570 shares indirectly through The Peetz Family Trust; the stock option is fully vested and expires March 11, 2029.
Mirum Pharmaceuticals, Inc. (MIRM) – Form 4 insider transaction filing. SVP & Global Controller Jolanda Howe reported three transactions between 1–3 July 2025.
- 1 Jul 2025: 1,041 restricted stock units (RSUs) converted into an equal number of common shares (Transaction Code M). Post-conversion ownership temporarily rose to 3,467 shares.
- 2 Jul 2025: 564 shares sold at $48.25 (Code S) to cover tax-withholding obligations tied to the RSU vesting.
- 3 Jul 2025: 477 shares sold at $49.08 under a pre-existing Rule 10b5-1 plan adopted 16 Dec 2024.
Following these actions, Howe’s direct beneficial ownership declined from 3,467 to 2,426 common shares. All 1,041 RSUs from the reported award are now fully settled, leaving no outstanding derivative securities.
The RSU grant vests in three equal annual installments that began on 1 Jul 2023. All reported transactions were executed by a single insider; no joint filings were made.